Table 1 Current standard of care regimens in multiple myeloma^a.

	Corticosteroids	Immunomodulatory agents	Proteasome inhibitors	Anti-CD38 mAbs	Alkylating agents	Anti-SLAMF7 mAb	Nuclear export inhibitor	Bcl-2 inhibitor
Currently available agents	DEX PRED	THAL LEN POM	BORT CFZ IXA	DARA ISA	Cy MEL	ELO	SEL	VEN
NDMM: ASCT eligible	DEX	THAL	BORT	—	—	—	—	—
	DEX	—	BORT	—	Cy^b	—	—	—
	DEX^c	LEN^c	BORT^c	—	—	—	—	—
	DEX	THAL	BORT	DARA	—	—	—	—
	DEX	LEN^d	BORT	DARA	—	—	—	—
	DEX	LEN	CFZ^d	—	—	—	—	—
NDMM: ASCT ineligible	DEX^e	LEN^e	BORT^f	—	—	—	—	—
	DEX^e	LEN^e	—	DARA^e	—	—	—	—
	DEX (low-dose)^f	LEN^f	—	—	—	—	—	—
	PRED	—	BORT	DARA	MEL	—	—	—
	DEX^g	—	BORT^g	—	Cy^g	—	—	—
RRMM:
With prior lenalidomide^h	DEX	POM	BORT or CFZ or IXA	—	—	—	—	—
	DEX	—	BORT or CFZ	DARA	—	—	—	—
	DEX	—	CFZ	ISA	—	—	—	—
	DEX	—	CFZ	—	Cy	—	—	—
	DEX	POM	—	—	—	ELO	—	—
	DEX	POM	—	DARA or ISA	—	—	—	—
	DEX	—	BORT	—	—	—	SEL	—
	DEX	—	BORT	—	—	—	—	VENⁱ
With prior daratumumab^h	DEX	POM^j	BORT	—	—	—	—	—
	DEX	POM^j	—	ISA	—	—	—	—
	DEX	—	CFZ	ISA	—	—	—	—
	DEX	LEN	—	—	—	ELO	—	—
	DEX	—	BORT	—	—	—	SEL	—
	DEX	—	BORT	—	—	—	—	VENⁱ
	DEX	POM	—	—	—	ELO	—	—

— agent not applicable for given combination regimen.
ASCT autologous stem cell transplant, BORT bortezomib, CFZ carfilzomib, Cy cyclophosphamide, DARA daratumumab, DEX dexamethasone, ELO elotuzumab, ISA isatuximab, IXA ixazomib, LEN lenalidomide, MEL melphalan, NDMM newly diagnosed multiple myeloma, POM pomalidomide, PRED prednisone, RRMM relapsed/refractory multiple myeloma, SEL selinexor, THAL thalidomide, VEN venetoclax.
^aEach row represents a combination regimen recommended for the disease state given in the first column.
^bMay be substituted for an immunomodulatory drug if not available in select countries.
^cMay be preferred based on risk-benefit profile.
^dStudies still ongoing on this combination.
^eUse for fit patients.
^fUse for unfit patients until disease progression.
^gAdditional lenalidomide-free regimen recommended in the United States.
^hEvidence supporting the efficacy of these regimens is limited in these populations.
ⁱPatients with t(11;14).
^jUse for patients with prior lenalidomide exposure.

Search